These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 19775602)

  • 1. Triple negative breast cancers: clinical and prognostic implications.
    Dawson SJ; Provenzano E; Caldas C
    Eur J Cancer; 2009 Sep; 45 Suppl 1():27-40. PubMed ID: 19775602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
    Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is triple-negative breast cancer?
    Irvin WJ; Carey LA
    Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of triple-negative breast cancer.
    de Ruijter TC; Veeck J; de Hoon JP; van Engeland M; Tjan-Heijnen VC
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):183-92. PubMed ID: 21069385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
    Cheang MC; Voduc D; Bajdik C; Leung S; McKinney S; Chia SK; Perou CM; Nielsen TO
    Clin Cancer Res; 2008 Mar; 14(5):1368-76. PubMed ID: 18316557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple negative tumours: a critical review.
    Reis-Filho JS; Tutt AN
    Histopathology; 2008 Jan; 52(1):108-18. PubMed ID: 18171422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.
    Kreike B; van Kouwenhove M; Horlings H; Weigelt B; Peterse H; Bartelink H; van de Vijver MJ
    Breast Cancer Res; 2007; 9(5):R65. PubMed ID: 17910759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
    Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
    BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance.
    Mohammed RA; Ellis IO; Mahmmod AM; Hawkes EC; Green AR; Rakha EA; Martin SG
    Mod Pathol; 2011 Jun; 24(6):774-85. PubMed ID: 21378756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept.
    Linn SC; Van 't Veer LJ
    Eur J Cancer; 2009 Sep; 45 Suppl 1():11-26. PubMed ID: 19775601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic triple-negative breast cancer.
    Rakha EA; Chan S
    Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic markers in triple-negative breast cancer.
    Rakha EA; El-Sayed ME; Green AR; Lee AH; Robertson JF; Ellis IO
    Cancer; 2007 Jan; 109(1):25-32. PubMed ID: 17146782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy of triple-negative breast cancer.
    Arslan C; Dizdar O; Altundag K
    Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
    Venkitaraman R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple-negative breast cancer: disease entity or title of convenience?
    Carey L; Winer E; Viale G; Cameron D; Gianni L
    Nat Rev Clin Oncol; 2010 Dec; 7(12):683-92. PubMed ID: 20877296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative/basal-like breast cancer: review.
    Rakha EA; Ellis IO
    Pathology; 2009 Jan; 41(1):40-7. PubMed ID: 19089739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.